Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib

被引：0
|
作者：
Duan, J. C. [1 ]
机构：
[1] Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
NSCLC; Third Generation EGFR-TKI; Resistance Mechanism;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-29
引用
收藏
页码：S652 / S652
页数：1
相关论文
共 50 条
  • [41] A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
    Chihara, Yusuke
    Takeda, Takayuki
    Goto, Yasuhiro
    Nakamura, Yoichi
    Tsuchiya-Kawano, Yuko
    Nakao, Akira
    Onoi, Keisuke
    Hibino, Makoto
    Fukuda, Minoru
    Honda, Ryoichi
    Yamada, Takahiro
    Taniguchi, Ryusuke
    Sakamoto, Sinjiro
    Date, Koji
    Nagashima, Seiji
    Tanzawa, Shigeru
    Minato, Koichi
    Nakatani, Koichi
    Izumi, Miiru
    Shimose, Takayuki
    Kishimoto, Junji
    Uchino, Junji
    Takayama, Koichi
    ONCOLOGIST, 2022, 27 (11): : 903 - E834
  • [42] TARGETED THERAPIES Optimal first-line therapy for NSCLC with EGFR mutations
    Neal, Joel W.
    Sequist, Lecia V.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (02) : 70 - 71
  • [43] Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC
    Zhang, Yi-chen
    Zhou, Qing
    Wu, Yi-Long
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1693 - 1701
  • [44] cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer
    Zhang, Huahua
    Zheng, Xiaochun
    Zhang, Yandong
    Wang, Jiangfeng
    FUTURE ONCOLOGY, 2024,
  • [45] EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Moore, Sara
    Wheatley-Price, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1788 - 1792
  • [46] ALK positive NSCLC Alecensa: The First-Line Therapeutic of Choice
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (05) : 297 - 298
  • [47] Clinical Outcomes After First-line EGFR Inhibitor Treatment for Patients with NSCLC, EGFR Mutation, and Poor Performance Status
    Okuma, Yusuke
    Hosomi, Yukio
    Nagamata, Makoto
    Yamada, Yuko
    Sekihara, Kuniko
    Kato, Kan
    Hishima, Tsunekazu
    Okamura, Tatsuru
    ANTICANCER RESEARCH, 2013, 33 (11) : 5057 - 5064
  • [48] First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?
    Passaro, Antonio
    Spitaleri, Gianluca
    de Marinis, Filippo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (08) : 799 - 801
  • [49] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Lu, Shun
    Shih, Jin-Yuan
    Jang, Tae-Won
    Liam, Chong-Kin
    Yu, Yongfeng
    ADVANCES IN THERAPY, 2021, 38 (05) : 2038 - 2053
  • [50] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Shun Lu
    Jin-Yuan Shih
    Tae-Won Jang
    Chong-Kin Liam
    Yongfeng Yu
    Advances in Therapy, 2021, 38 : 2038 - 2053
12345